Marinomed Biotechnologie GmbH Company Profile
Marinomed is a biopharmaceutical company discovering and developing innovative anti-viral and immunological treatments.
Marinomed develops therapies against respiratory diseases based on its innovative anti-viral respiratory technology platform mavirex. Safety and efficacy of the mavirex technology have already been proven in clinical trials. The huge potential of the technology is reflected by Marinomed´s first product which was derived from this platform. The product is an anti-viral nasal spray marketed against Common Cold. Other anti-viral products targeted by mavirex are in the indications Influenza, Common Cold as well as combination therapies in the respiratory field, especially for indications where respiratory viruses cause a worsening of the disease, eg. Asthma, Allergic Rhinitis and COPD.
In addition, the Company develops novel “first in class” treatments against type I allergy and autoimmune diseases.
Marinomed is located in Vienna, Austria, and was founded in March 2006 as a spin-off from the Veterinary University of Vienna.
Location
Veterinärplatz 1
Vienna
1210
Austria
Contact
Phone: +43 1 25077 4460
Fax: +43 1 25077 4493
Email: office@marinomed.com
News Articles
Marinomed granted Chinese patent for anti-viral polymer
Austrian company Marinomed Biotechnologie GmbH, which is focused on the development of innovative therapies for respiratory diseases, has been granted a patent entitled ‘Antiviral polymer’ by the...
Vienna, Austria, 27 October 2011- Marinomed Biotechnologie GmbH, a company focused on the development of innovative therapies for respiratory diseases, announced today that it has appointed Dr. A...
Marinomed Granted Chinese Patent for Antiviral Polymer
Vienna, Austria – 19 November 2012 – Marinomed Biotechnologie GmbH, a company focused on the development of innovative therapies for respiratory diseases, today announced that it has been gran...
Marinomed's MAM-06.301 Achieves Preclinical POC - Study published in BMC Immunology (CollegeHill)
Vienna, Austria, 25 May, 2010 - Marinomed Biotechnologie GmbH, a company focused on the development of innovative therapies for respiratory diseases, announced today that MAM-06.301 has achieved...
Marinomed’s Antiviral Effective in Clinical Trial for Common Cold
Study published in Respiratory Research Vienna, Austria, 11 August 2010 - Marinomed Biotechnologie GmbH, a company focused on the development of innovative therapies for respiratory diseases, a...
Marinomed wins STEP award in "Market-Customer" category and special award for strategic partnerships
Vienna, Austria, 19 November 2010 - Marinomed Biotechnologie GmbH, a company focused on the development of innovative therapies for respiratory diseases, today announced that it has won the &euro...
Marinomed's Iota-Carrageenan Nasal Spray Achieves Positive Clinical Results Against Common Cold
Results Presented in an Oral Presentation at ISRVI in Istanbul, March 23-26th Vienna, Austria- 21 March 2012 - Marinomed Biotechnologie GmbH, a company focused on the development of innovative...
Marinomeds Iota-Carrageenan Effective Against H1N1 - Study published in PLoS ONE
Vienna, Austria, 15th December 2010 - Marinomed Biotechnologie GmbH, a company focused on the development of innovative therapies for respiratory diseases, today announced that in vitro and in-vi...
Drugs and Medications
Firmagon [Ferring Pharmaceuticals Inc.]
These highlights do not include all the information needed to use FIRMAGON safely and effectively. See full prescribing information for FIRMAGON. FIRMAGON® (degarelix for injection) for subcutaneous...
PubMed Articles
DNA methylation, a key player in pluripotency.
Muscle wasting (sarcopenia/cachexia) and malnutrition.
Contents: biotechnologie journal 4/2012.
Regulatory and Metabolic Networks for Amino Acid Production by Corynebacterium glutamicum.
Structural basis for hijacking of cellular LxxLL motifs by papillomavirus E6 oncoproteins.
E6 viral oncoproteins are key players in epithelial tumors induced by papillomaviruses in vertebrates, including cervical cancer in humans. E6 proteins target many host proteins by specifically intera...
Clinical Trials
None
Companies
Marinomed is a biopharmaceutical company discovering and developing innovative anti-viral and immunological treatments. Marinomed develops therapies against respiratory diseases based on its innova...
Centre québécois d'innovation en biotechnologie
Le Centre québécois d'innovation en biotechnologie (CQIB), un organisme privé sans but lucratif fondé en 1995, est un incubateur d'entreprises spécialisé en biotechnologie. Accompagner, Innover,...
AnalytiCon AG Biotechnologie-Pharmazie
AnalytiCon AG Biotechnologie Pharmazie provides quality control, research and development.
Just two decades ago, biotechnology in was taking its first developmental steps in the marketplace. Today, it is firmly established as a commercial branch. This is the picture emerging from the recen...
BIOTECHNOLOGIE KEMPE GMBH has been located in Berlin for more than twenty years (since 2004 on the outskirts of the city). We focus on development and construction of measuring and control equipment f...
More Information about "Marinomed Biotechnologie GmbH" on BioPortfolio
We have published hundreds of Marinomed Biotechnologie GmbH news stories on BioPortfolio along with dozens of Marinomed Biotechnologie GmbH Clinical Trials and PubMed Articles about Marinomed Biotechnologie GmbH for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Marinomed Biotechnologie GmbH Companies in our database. You can also find out about relevant Marinomed Biotechnologie GmbH Drugs and Medications on this site too.
